In patients with chronic, eosinophil-rich, neoplasms exhibiting FIP1L1-PDGFRA or other imatinib-sensitive PDGFR variants, imatinib is regarded standard first-line therapy [10, 11, 16–18, 105–109, 130–132]. Here, FIP1L1 is linked to neoplasm.